# Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of INGREZZA® (valbenazine) Capsules Across a Broad Range of Patients
Canonical URL: https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-presents-new-clinically-meaningful-response-data-on-treatment-of-tardive-dyskinesia-reinforcing-the-efficacy-of-ingrezzar-valbenazine-capsules-across-a-broad-range-of-patients
Ticker: NBIX
Company: Neurocrine Biosciences
Source: Neurocrine Biosciences
Published: 2026-06-25 13:46 EST
Original Source URL: https://neurocrine.gcs-web.com
## Summary

New 48-week KINECT ® 4 post-hoc analysis shows 94% of participants treated with INGREZZA achieved either symptomatic remission or a clinically meaningful response (≥30% reduction from baseline in Abnormal Involuntary Movement Scale total score); INGREZZA is the only vesicular monoamine transporter

## Article Body
New 48-week KINECT ® 4 post-hoc analysis shows 94% of participants treated with INGREZZA achieved either symptomatic remission or a clinically meaningful response (≥30% reduction from baseline in Abnormal Involuntary Movement Scale total score); INGREZZA is the only vesicular monoamine transporter
## Recent Company News
- 2026-07-01 20:05 EST — [Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia](https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-initiates-phase-2-study-of-crinecerfont-in-pediatric-pati-8fe2e2b9) — Source: Neurocrine Biosciences
- 2026-06-25 13:46 EST — [Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026](https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-presents-first-retrospective-case-series-of-crenessityr-crinecerfont-in-patients-with-classic-congenital-adrenal-hyperplasia-due-to-11-hydroxylase-deficiency-at-endo-2026) — Source: Neurocrine Biosciences
- 2026-06-25 13:46 EST — [Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period](https://biopharmsignal.com/news/NBIX/soleno-therapeutics-presents-new-vykatr-xr-diazoxide-choline-data-at-endo-2026-demonstrating-meaningful-and-durable-improvements-in-hyperphagia-and-behavioral-symptoms-in-prader-willi-syndrome-following-randomized-withdrawal-period) — Source: Neurocrine Biosciences
- 2026-06-25 13:46 EST — [Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026](https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-presents-new-two-year-crenessityr-crinecerfont-data-demonstrating-improved-growth-measures-in-pediatric-patients-with-classic-congenital-adrenal-hyperplasia-at-endo-2026) — Source: Neurocrine Biosciences
- 2026-06-25 13:46 EST — [Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026](https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-presents-new-two-year-crenessityr-crinecerfont-data-demonstrating-improvements-in-cardiometabolic-outcomes-in-adults-with-classic-congenital-adrenal-hyperplasia-at-endo-2026) — Source: Neurocrine Biosciences
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)